SLC5A2 and type 2 diabetes mellitus: Yet, it is of the utmost significance, in the time of this COVID-19 pandemic, the exceptional risk of diabetic ketoacidosis (DKA) associated with SGLT2 inhibitors among vulnerable patient categories, such as long-standing T2D patients with marked β-cell insufficiency or patients with autoimmune diabetes, during an intercurrent illness [44].